Bridge Biotherapeutics and HitGen Collaborate on Novel Cancer Therapeutics
Friday, August 23, 2024
Bridge Biotherapeutics has entered into a joint research agreement with HitGen. Building on the success of initial hit identification from HitGen's DNA-encoded library (DEL), the collaboration aims to advance these novel hits into promising drug candidates for cancer treatment.
Bridge Biotherapeutics plans to expand its oncology portfolio, which currently focuses on EGFR inhibitors for lung cancer, by developing new anticancer drug candidates targeting undisclosed mechanisms. The joint research with HitGen is expected to accelerate the identification of effective compounds, their optimization, and the securing of lead candidates within the next year.
HitGen, a global leader in DEL technology and its application to early-stage small molecule drug discovery, boasts a platform with over 1.2 trillion small molecules. The efficiency of HitGen’s screening process has facilitated drug discovery projects for numerous organizations worldwide.
In recent years, HitGen has evolved into an integrated drug discovery company, focusing on DEL, synthetic therapeutic oligonucleotide (STO), targeted protein degradation (TPD), fragment-based drug discovery, and structure-based drug design (FBDD/SBDD).
Collaborating with HitGen will accelerate the efforts to discover new targeted anticancer drugs committed to developing treatments that are effective even against genetically mutated cancers, which have traditionally been challenging to target.
This collaboration will contribute to the rapid advancement of new anticancer drug discoveries, leveraging the expertise of both companies.
Bridge Biotherapeutics has recently initiated the fourth cohort in the Phase 1 clinical trial for its lead candidate drug, BBT-207, aimed at treating non-small cell lung cancer. Through this collaboration with HitGen, the company is reinforcing its commitment to discovering new anticancer drugs and strengthening its oncology portfolio.
Source:prnasia.com
